Elusys Therapeutics leverages immune-stimulatory and immune-derived therapies to combat infectious disease. Our anthrax antitoxin obiltoxaximab, licensed as ANTHIM® in the United States and Canada and as NYXTHRACIS® in the Great Britain and the European Union, is a medical countermeasure to mitigate the effect of anthrax exposure after a natural incident or intentional attack. Our mission is to accelerate the development and commercialization of novel biodefense solutions to defend tomorrow today.